163 related articles for article (PubMed ID: 18853992)
1. Azathioprine: when less is more.
Duley JA; Florin TH
J Gastroenterol Hepatol; 2008 Sep; 23(9):1317-9. PubMed ID: 18853992
[No Abstract] [Full Text] [Related]
2. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
Andoh A; Tsujikawa T; Ban H; Hashimoto T; Bamba S; Ogawa A; Sasaki M; Saito Y; Fujiyama Y
J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197
[TBL] [Abstract][Full Text] [Related]
3. Monitoring 6-thioguanine nucleotide concentrations in Japanese children and adolescents with inflammatory bowel disease.
Ohtsuka Y; Arai K; Aoyagi Y; Fujii T; Yamakawa Y; Ohtani K; Ikuse T; Baba Y; Inage E; Kudo T; Suzuki R; Nagata S; Shimizu T
J Gastroenterol Hepatol; 2010 Oct; 25(10):1626-30. PubMed ID: 20880170
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].
Schwab M; Herrlinger K; Schaeffeler E; Stange EF
Dtsch Med Wochenschr; 2003 Feb; 128(8):378-85. PubMed ID: 12594624
[No Abstract] [Full Text] [Related]
5. Next steps on the thiopurine methyltransferase 6-thioguanine nucleotide pathway.
Colletti RB
J Pediatr Gastroenterol Nutr; 2006 Sep; 43(3):282-3. PubMed ID: 16954947
[No Abstract] [Full Text] [Related]
6. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.
Cuffari C; Hunt S; Bayless T
Gut; 2001 May; 48(5):642-6. PubMed ID: 11302961
[TBL] [Abstract][Full Text] [Related]
7. Thiopurines best practice.
Friedman A
J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():6-7. PubMed ID: 26990458
[No Abstract] [Full Text] [Related]
8. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic.
Smith M; Blaker P; Patel C; Marinaki A; Arenas M; Escuredo E; Anderson S; Irving P; Sanderson J
Int J Clin Pract; 2013 Feb; 67(2):161-9. PubMed ID: 23253089
[TBL] [Abstract][Full Text] [Related]
9. Erythrocyte mean corpuscular volume as a surrogate marker for 6-thioguanine nucleotide concentration monitoring in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine.
Thomas CW; Lowry PW; Franklin CL; Weaver AL; Myhre GM; Mays DC; Tremaine WJ; Lipsky JJ; Sandborn WJ
Inflamm Bowel Dis; 2003 Jul; 9(4):237-45. PubMed ID: 12902847
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine therapy: when to start and when to stop.
McGovern DP; Travis SP
Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):219-23. PubMed ID: 12610314
[TBL] [Abstract][Full Text] [Related]
11. Prediction of 6-thioguanine nucleotides levels in Japanese patients with inflammatory bowel diseases during long-term thiopurine administration.
Kochi S; Matsumoto T; Esaki M; Jo Y; Iida M
Scand J Gastroenterol; 2010 May; 45(5):608-14. PubMed ID: 20163203
[TBL] [Abstract][Full Text] [Related]
12. Thiopurines in inflammatory bowel disease: new strategies for optimization of pharmacotherapy?
Derijks LJ; Hommes DW
Curr Gastroenterol Rep; 2006 Apr; 8(2):89-92. PubMed ID: 16533469
[No Abstract] [Full Text] [Related]
13. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.
Lowry PW; Franklin CL; Weaver AL; Pike MG; Mays DC; Tremaine WJ; Lipsky JJ; Sandborn WJ
Gut; 2001 Nov; 49(5):665-70. PubMed ID: 11600469
[TBL] [Abstract][Full Text] [Related]
14. Thiopurine-S-methyltransferase genotype and the response to azathioprine in inflammatory bowel disease.
Stocco G; Martelossi S; Decorti G; Bartoli F; Ventura A
Aliment Pharmacol Ther; 2007 Oct; 26(7):1083-4; author reply 1084-5. PubMed ID: 17877516
[No Abstract] [Full Text] [Related]
15. Monitoring of azathioprine/6-mercaptopurine treatment in children with IBD is not necessary.
Griffiths AM
Inflamm Bowel Dis; 2003 Nov; 9(6):389-91; discussion 392-3. PubMed ID: 14671489
[No Abstract] [Full Text] [Related]
16. [Pharmacogenetic study of thiopurine S-methyltransferase (TPMT) and thiopurine toxicity].
Corominas H; Díaz C; Vázquez G; Baiget M
Rev Esp Enferm Dig; 2002 Oct; 94(10):635-6. PubMed ID: 12647415
[No Abstract] [Full Text] [Related]
17. [Optimized thiopurine treatment in chronic inflammatory bowel disease].
Kiszka-Kanowitz M; Theede K; Nielsen AM
Ugeskr Laeger; 2015 Jun; 177(26):1253-5. PubMed ID: 26550625
[TBL] [Abstract][Full Text] [Related]
18. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
Derijks LJ; de Jong DJ; Gilissen LP; Engels LG; Hooymans PM; Jansen JB; Mulder CJ
Eur J Gastroenterol Hepatol; 2003 Jan; 15(1):63-7. PubMed ID: 12544696
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of AZA/6-MP treatment in children with IBD is necessary.
Dubinsky MC
Inflamm Bowel Dis; 2003 Nov; 9(6):386-8; discussion 392-3. PubMed ID: 14671488
[No Abstract] [Full Text] [Related]
20. Does lymphopenia or macrocytosis reflect 6-thioguanine levels in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine?
Heerasing NM; Ng JF; Dowling D
Intern Med J; 2016 Apr; 46(4):465-9. PubMed ID: 26425841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
